Drug Farm, a clinical-stage biotechnology company, has secured $55 million in the first closing of its Series D financing round. The funding was co-led by the Shanghai Pudong Leading Zone Investment Center and Shanghai Puxing Xietong Private Equity Partnership. This capital will advance the company's pipeline of first-in-class therapies developed using its proprietary artificial intelligence platforms.
Investor Confidence in a Novel Approach
The financing attracted new investors like Zhikai Capital and Keyuan Pharmaceutical, demonstrating strong market confidence in the company's direction. Existing shareholders, including BVCF and YD Capital, also participated, reaffirming their long-term support for Drug Farm's mission. Haoyue Capital served as the exclusive financial adviser for the transaction.
Dr. Xu Tian, founder and chairman of Drug Farm, called the investment a pivotal milestone in developing innovative medicines for patients globally. He noted the backing from investors reflects trust in the company's scientific capabilities and strategic vision. This support is expected to help create significant value for both patients and shareholders.
Fueling Late-Stage Clinical Development
A primary focus for the new capital will be advancing Drug Farm's lead drug candidates, DF-003 and DF-006. CEO Dr. Henri Lichenstein confirmed the funds provide essential resources to accelerate these programs through critical development stages. He highlighted DF-003 as a pioneering AI-aided, first-in-class drug candidate progressing toward late-stage clinical trials.
Specifically, the financing will support pivotal development for DF-003 in patients with ROSAH syndrome, a rare genetic inflammatory disorder. It will also enable proof-of-concept studies for its potential use in atherosclerotic cardiovascular disease. Concurrently, proceeds will fund the continued clinical development of DF-006 for chronic hepatitis B.
AI-Powered Discovery Platforms
Drug Farm's innovative approach is rooted in its proprietary IDInVivo+ and MedChem5 platforms, which integrate advanced technologies. According to COO Dr. Xu Cong, these systems combine human genetics, in vivo biology, and AI-enabled medicinal chemistry. This synergy allows the company to efficiently identify and validate novel drug targets for development.
The platforms are instrumental in moving first-in-class drug candidates from discovery into clinical trials with greater precision. This financing will empower the company to leverage its technology to develop more therapies for patients with unmet needs. The company's focus remains on metabolic and autoimmune diseases where new treatments are urgently required.
A Closer Look at the Lead Candidates
DF-003 is an investigational small-molecule drug designed to inhibit alpha-kinase 1 (ALPK1), a protein linked to inflammatory signaling. The candidate has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. FDA for treating ROSAH syndrome. The company is also exploring its efficacy in broader cardiovascular and renal disease applications.
The company's second lead candidate, DF-006, is a first-in-class oral immunomodulatory drug being evaluated for chronic hepatitis B. It functions as an ALPK1 agonist, designed to stimulate innate immune responses within the liver to combat the virus. Early clinical evaluations have shown encouraging antiviral activity, and Drug Farm is advancing its development.
This $55 million Series D financing marks a transformative moment for Drug Farm, providing capital to accelerate its most promising clinical programs. By advancing its AI-discovered candidates, DF-003 and DF-006, the company is poised to make strides in treating rare and chronic diseases. The strong investor support underscores confidence in Drug Farm's unique technology and its potential to deliver breakthrough therapies.